Navigation Links
Daiichi Sankyo, Inc. Acquires First US-Based Packaging and Manufacturing Facility

PARSIPPANY, N.J., Feb. 15, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI), today announced the acquisition of a 140,000 square foot facility in Bethlehem Township, Pennsylvania from Amcor, a global packaging manufacturer. This acquisition, worth $10.25MM, enables DSI to leverage existing resources to more cost-effectively supplement its operations rather than build a new facility. The facility is expected to be operational in the summer or early fall of 2011 and is expected to package some of company's portfolio of marketed products, such as Benicar®, Welchol® and Azor®. Once the facility is operating at full capacity, it is expected to assume an increasing responsibility for packaging the entire line of marketed products in the U.S., as well as perform compounding operations for select products.

"Creating and protecting family-sustaining jobs in Pennsylvania is one of this administration's highest priorities, so I'm pleased to announce Daiichi Sankyo's decision to select PA as the site for its first-ever U.S. packaging and manufacturing plant," said Governor Corbett.  "By creating approximately 80 jobs, continuing the productive use of a facility that would otherwise have been closed, and injecting more than $15 million in outside investment into the local economy, this project will have a definite positive impact on the Lehigh Valley region."

DSI conducted a comprehensive national site search with McCallum Sweeney Consulting to identify an existing facility that mirrored the company's packaging goals and specifications. After a national screening of 62 sites in 48 communities in 12 states, the company selected the site in Bethlehem. Upon completing the initial phase of the renovation, DSI plans to hire approximately 80 new employees and will create a positive economic impact through related purchasing of goods and services from local businesses.

"This acquisition diversifies our company's capabilities and allows us to streamline our operations and minimize commercialization risk by exerting greater control over the life cycle of our products, from research and development through packaging and distribution," said Jeff Lane, Vice President of Operations, Daiichi Sankyo, Inc. "We are excited to be opening a facility in Bethlehem and look forward to a productive future working relationship and becoming a part of the local community. The Governor's Action Team, Lehigh Valley Economic Development Corporation, the Northampton County and City of Bethlehem were invaluable partners in helping to make this milestone possible."

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group.  For more information on Daiichi Sankyo, Inc., please visit

SOURCE Daiichi Sankyo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
6. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
7. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
10. Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
11. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
Post Your Comments:
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):